Dermata Therapeutics, Inc. carries no debt; cash flow comfortably covers obligations.

Dermata Therapeutics, Inc.'s free cash flow has decreased 69.39K% from $-11.16M last year to $-7.76G, signaling decreasing performance

Dermata Therapeutics, Inc.'s debt to equity ratio is 0.00, which means that the company's assets are healthy financed, signaling financial stability. READ MORE: A ratio under 0.60 means the company finances its assets with own equity, signaling financial stability and good management.

Dermata Therapeutics, Inc. has insufficient data to evaluate this check.

Dermata Therapeutics, Inc. has negative EBITDA, making leverage ratio unreliable

Dermata Therapeutics, Inc. earns at least as much interest as it pays. Interest obligations are fully covered.

Dermata Therapeutics, Inc. has insufficient data to evaluate this check.

Dermata Therapeutics, Inc.'s short-term assets of $7.86M exceed its short-term liabilities of $1.64M

Dermata Therapeutics, Inc.'s return on assets of 0.00% is lower than the 5.00% threshold, indicating inefficient asset utilization

Dermata Therapeutics, Inc.'s return on equity of -127.91%, is lower than 15.00%, indicating bad performance

Dermata Therapeutics, Inc.'s operating cash flow is lower than its net income, indicating that earnings may not be fully backed by cash generation

Dermata Therapeutics, Inc. had positive net income in only 0.00 out of 5 years, indicating unstable earnings

Dermata Therapeutics, Inc. has negative free cash flow, indicating the company is burning cash rather than generating it

Dermata Therapeutics, Inc. has negative free cash flow, indicating cash burn

Dermata Therapeutics, Inc.'s yearly earnings has increased -38.49% since last year from $-12.29M to $-7.56M, signaling increasing performance

Dermata Therapeutics, Inc.'s yearly revenue has increased 0.00% since last year from $0.00 to $0.00, signaling increasing performance

ROIC -114.77% (Source: FMP key-metrics). Below the 5% partial-credit threshold. Score: 0 of 2. The 5% and 10% cutoffs anchor to typical US weighted-average cost of capital. Below 5% indicates the company is not generating returns above its likely cost of capital under this definition of invested capital. Invested capital here includes equity, non-current liabilities (pension obligations, deferred taxes, lease obligations), and short-term debt. Cash is not subtracted. Companies with substantial float, lease portfolios, or cash holdings will score lower under this definition than under narrower operating-capital definitions. See methodology.

Dermata Therapeutics, Inc. has insufficient revenue history to calculate 3-year revenue CAGR.

Dermata Therapeutics, Inc. had revenue growth in 5.00 out of 5 years, indicating consistent revenue performance

Dermata Therapeutics, Inc. had positive ROE in only 0.00 out of 5 years, indicating inconsistent returns on equity

Dermata Therapeutics, Inc. is undervalued relative to its fair value price of 8.14K based on Discounted Cash Flow model

Dermata Therapeutics, Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

Dermata Therapeutics, Inc. is undervalued relative to its fair value price of 10.96K based on EBITDA multiple model

Dermata Therapeutics, Inc. has negative or missing EBITDA, making EV/EBITDA ratio unreliable

Dermata Therapeutics, Inc. has insufficient data to evaluate this check.

Dermata Therapeutics, Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

Dermata Therapeutics, Inc. has a price-to-book ratio of 0.79x, which is below the 5.00x threshold, indicating reasonable valuation relative to its book value

Dermata Therapeutics, Inc. has a price-to-sales ratio of 999.00x, which exceeds the 8.00x threshold, indicating the stock may be overvalued relative to its revenue